Cas 348165-65-1,Carbamic acid, [(1-methylcyclopentyl)methyl]-, ethyl ester (9CI)

348165-65-1

Post Buying Request

Basic information

Product Name: Carbamic acid, [(1-methylcyclopentyl)methyl]-, ethyl ester (9CI)
Synonyms: Carbamic acid, [(1-methylcyclopentyl)methyl]-, ethyl ester (9CI)
CAS NO:348165-65-1
Molecular Formula: C10H19NO2
Molecular Weight: 185.26336
EINECS: N/A
Product Categories: CYCLOPENTANE
Mol File: 348165-65-1.mol

Chemical Properties

Melting Point: N/A
Boiling Point: N/A
Flash Point: N/A
Appearance: /
Density: N/A
Refractive Index: N/A
Storage Temp.: N/A
Solubility: N/A
CAS DataBase Reference: Carbamic acid, [(1-methylcyclopentyl)methyl]-, ethyl ester (9CI)(CAS DataBase Reference)
NIST Chemistry Reference: Carbamic acid, [(1-methylcyclopentyl)methyl]-, ethyl ester (9CI)(348165-65-1)
EPA Substance Registry System: Carbamic acid, [(1-methylcyclopentyl)methyl]-, ethyl ester (9CI)(348165-65-1)

Safety Data

Hazard Codes: N/A
Statements: N/A
Safety Statements: N/A
WGK Germany:
RTECS:
HazardClass: N/A
PackingGroup: N/A
Hazardous Substances Data: 348165-65-1(Hazardous Substances Data)

Suppliers
Usage
Upstream product
Downstream Products
Article

348165-65-1 Suppliers

Recommended suppliers

348165-65-1 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 348165-65-1 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 3,4,8,1,6 and 5 respectively; the second part has 2 digits, 6 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 348165-65:
(8*3)+(7*4)+(6*8)+(5*1)+(4*6)+(3*5)+(2*6)+(1*5)=161
161 % 10 = 1
So 348165-65-1 is a valid CAS Registry Number.

348165-65-1Upstream product

348165-65-1Downstream Products

348165-65-1Relevant academic research and scientific papers

N-heterocyclic inhibitors of TNF-alpha expression

-

, (2008/06/13)

N-heterocyclic compounds that block cytokine production via inhibition of p38 kinase are disclosed. In one embodiment, compounds of the present invention are represented by Formula I: Methods of production, pharmaceutical compositions and methods of treating conditions associated with inappropriate p38 kinase activity or TNF-α expression utilizing compounds of the present invention are also disclosed.

Post a RFQ

Cas No.:

Product Name:

Quantity:

Email:

Company name:

Valid Period:

Detailed Requirements:

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

What can I do for you?
Get Best Price

Get Best Price for 348165-65-1